JANUARY 18, 2022, OXFORD, UK – Cancer Research UK, Vaccitech plc (Nasdaq: VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient dosed in the MAGE trial, which is testing a novel immunotherapeutic, VTP-600*, in patients with the most common type of lung cancer.
The phase I/IIa trial is expected to enrol approximately 86 people who have been newly diagnosed with non-small cell lung cancer (NSCLC)** and will be testing the safety and initial efficacy of VTP-600 in these patients. VTP-600 will be given in combination with the current first line treatment for NSCLC***.
If further clinical trials are successful, VTP-600 could prove to be a powerful new treatment for a group of patients in need of better options.
Depending on its effectiveness in NSCLC, VTP-600 could be evaluated in other types of cancer in the future, including breast, bowel, bladder and melanoma.
Cancer Research UK’s Centre for Drug Development (CDD) is managing and providing significant funding for the phase I/IIa trial. Vaccitech Oncology Limited (VOLT)****, a strategic collaboration between Vaccitech and Ludwig, are supplying VTP-600 for the trial.